Updated on 2024/06/24

写真a

 
KAGEYAMA YUKI
 
Organization
Graduate School of Medicine Department of Clinical Medical Science Lecturer
School of Medicine Department of Medical Science
Title
Lecturer
Affiliation
Institute of Medicine
Affiliation campus
Abeno Campus

Position

  • Graduate School of Medicine Department of Clinical Medical Science 

    Lecturer  2022.04 - Now

  • School of Medicine Department of Medical Science 

    Lecturer  2022.04 - Now

Degree

  • 博士(医学) （ Osaka City University ）

Papers

  • Hoarding medication and suicide attempts with 1180 tablets of mirtazapine overdose: A case report

    Kageyama Y.

    Psychiatry and Clinical Neurosciences Reports   3 ( 2 )   2024.06

    　More details

  • Significant Weight Gain With the Administration of Lurasidone and Valproic Acid in Schizophrenia and Bipolar Disorder Patients.

    Okura S, Deguchi Y, Cho T, Kageyama Y, Inoue K

    Cureus   15 ( 11 )   e49005   2023.11（ ISSN:2168-8184 ）

    　More details

  • Relationship between circulating mitochondrial DNA and microRNA in patients with major depression

    Ogata H.

    Journal of Affective Disorders   339   538 - 546   2023.10（ ISSN:01650327 ）

    　More details

  • Mitochondrial Gene Abnormality Complicated by Perinatal-Onset Depression

    Kageyama Y.

    Primary Care Companion for CNS Disorders   25 ( 5 )   2023

    　More details

  • Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression.

    Atake K, Hori H, Kageyama Y, Koshikawa Y, Igata R, Tominaga H, Katsuki A, Bando H, Sakai S, Nishida K, Takekita Y, Kato T, Kinoshita T, Kato M

    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry   23 ( 10 )   1 - 9   2022.03（ ISSN:1562-2975 ）

    　More details

  • Intra-individual state-dependent comparison of plasma mitochondrial DNA copy number and IL-6 levels in patients with bipolar disorder.

    Kageyama Y, Deguchi Y, Kasahara T, Tani M, Kuroda K, Inoue K, Kato T

    Journal of affective disorders   299   644 - 651   2022.02（ ISSN:0165-0327 ）

    　More details

  • Nervonic acid level in cerebrospinal fluid is a candidate biomarker for depressive and manic symptoms: A pilot study.

    Kageyama Y, Deguchi Y, Hattori K, Yoshida S, Goto YI, Inoue K, Kato T

    Brain and behavior   11 ( 4 )   e02075   2021.04

    　More details

  • The relationship between circulating mitochondrial DNA and inflammatory cytokines in patients with major depression.

    Kageyama Y, Kasahara T, Kato M, Sakai S, Deguchi Y, Tani M, Kuroda K, Hattori K, Yoshida S, Goto Y, Kinoshita T, Inoue K, Kato T

    Journal of affective disorders   233   15 - 20   2018.06（ ISSN:0165-0327 ）

    　More details

  • Plasma Nervonic Acid Is a Potential Biomarker for Major Depressive Disorder: A Pilot Study.

    Kageyama Y, Kasahara T, Nakamura T, Hattori K, Deguchi Y, Tani M, Kuroda K, Yoshida S, Goto YI, Inoue K, Kato T

    The international journal of neuropsychopharmacology   21 ( 3 )   207 - 215   2018.03（ ISSN:1461-1457 ）

    　More details

  • Search for plasma biomarkers in drug-free patients with bipolar disorder and schizophrenia using metabolome analysis.

    Kageyama Y, Kasahara T, Morishita H, Mataga N, Deguchi Y, Tani M, Kuroda K, Hattori K, Yoshida S, Inoue K, Kato T

    Psychiatry and clinical neurosciences   71 ( 2 )   115 - 123   2017.02（ ISSN:1323-1316 ）

    　More details

  • 【精神医学のバイオマーカー革新】双極性障害および統合失調症の薬剤非服用患者におけるメタボローム解析を用いた血漿バイオマーカーの探索(【Innovations of Biomarkers in Psychiatry】Search for plasma biomarkers in drug-free patients with bipolar disorder and schizophrenia using metabolome analysis)

    Kageyama Yuki, Kasahara Takaoki, Morishita Hiromasa, Mataga Nobuko, Deguchi Yasuhiko, Tani Munehide, Kuroda Kenji, Hattori Kotaro, Yoshida Sumiko, Inoue Koki, Kato Tadafumi

    Psychiatry and Clinical Neurosciences   71 ( 1-2 )   115 - 123   2017.02（ ISSN:1323-1316 ）

    　More details

    2週間以上にわたり向精神病薬を服用していない双極性障害(BD)患者、統合失調症(SZ)患者、大うつ病(MDD)患者の血漿検体を用いて新たなバイオマーカーの探索を実施した。対象はBD患者6例(男性1例、女性5例、平均41.8±13.3歳)、SZ患者17例(男性8例、女性9例、平均33.6±15.7歳)、MDD患者9例(男性3例、女性6例、平均39.1±10.2歳)とした。血漿代謝産物の分析にはキャピラリー電気泳動飛行時間型質量分析を用いた。SZ群では対照群と比較してクレアチン値が低く、2-ヒドロキシ酪酸値が高かった。シトルリンはBD群において対照群に比べて有意に減少していたが、投薬治療を受けるBD群では再現されなかった。コリン値はSZ群においてMDD群よりも低かった。患者の症状と代謝産物との間に有意な相関は認められなかった。BDのバイオマーカーには、ドーパミン代謝産物であるNメチルノルサルソリノールが候補物質として挙げられた。

  • 精神疾患合併妊娠137例における胎児・新生児の合併症と服薬との関連性について

    高田 宏宗, 柳田 誠, 富岡 孝仁, 金井 講治, 高屋 雅彦, 木村 亮, 影山 祐紀, 竹村 昌彦, 丸山 朋子, 田尻 仁, 松永 秀典

    総合病院精神医学   25 ( 3 )   287 - 294   2013.07（ ISSN:0915-5872 ）

    　More details

    2007年7月から2012年3月の大阪府立急性期・総合医療センターで出産した精神疾患合併妊婦で精神科も受診した出産137例について、後方視的に母親の分娩年齢、精神疾患の診断、向精神薬の服薬の有無を調べた。妊婦の精神疾患は、器質性精神障害1例、精神作用物質による障害7例、統合失調症24例、気分障害27例、神経症性およびストレス関連障害53例、摂食障害2例、人格障害15例、精神遅滞5例、てんかん3例であった。妊娠12週以前に内服していた向精神薬の内訳は抗精神薬40例、抗うつ剤43例、抗不安剤・睡眠導入剤77例、抗てんかん薬26例、その他11例であった。出産については、流産6例、死産1例、末梢性肺動脈狭窄1例、末梢性肺動脈狭窄+漏斗胸1例、口蓋裂1例、多嚢胞形成腎1例、動脈管開存+心室中隔欠損1例、ダウン症1例、水腎症1例、耳介低位1例を認めた。妊娠初期に向精神薬を服用していた症例では、高齢妊婦および多剤併用が奇形発生のリスクを高めることが示唆された。

  • Examination of pregnancies in patients with psychiatric disorders: the relationships between fetal or neonatal complications and maternal psychotropic drug use

    Takada Hiromune, Yanagida Makoto, Tomioka Takahito, Kanai Koji, Takaya Masahiko, Kimura Ryo, Kageyama Yuki, Takemura Masahiko, Maruyama Tomoko, Tajiri Hitoshi, Matsunaga Hidenori

    Japanese Journal of General Hospital Psychiatry   25 ( 3 )   287 - 294   2013（ ISSN:09155872 ） （ eISSN:21864810 ）

    　More details

    <p>In this study, we assessed the relationship between the use of psychotropic drugs and fetal and neonatal complications encountered in patients with psychiatric disorders. From July 2007 to March 2012, 137 mothers with psychiatric disorders gave birth in our hospital. Ninety-nine mothers used psychotropic drugs within 12 weeks of pregnancy. There were 7 cases of miscarriage. However, they were not associated with the use of psychotropic drugs. There were 8 cases of malformation. All these mothers used psychotropic drugs within 12 this period. Among them, older mothers were more vulnerable to malformation risk (≥35 years: 6/30 cases; <35 years: 2/69 cases; p=0.0041). The number of psychotropic drugs used was associated with higher malformation risk (p=0.0021). Complications other than miscarriage and malformation were classified as complications that would be induced by the use of psychotropic drugs just before delivery and other complications. The incidence of each complication was 50% higher in the group that used psychotropic drugs after 12 weeks of pregnancy than in the group that did not. Thus, our findings indecate that the co-existence of psychotropic drug use, especially multidrug use, and older age may be associated with malformation in neonates of mothers with psychiatric disorders.</p>

    DOI： 10.11258/jjghp.25.287

    CiNii Article

▼display all

Presentations

▼display all

Grant-in-Aid for Scientific Research

  • investigation of novel biomarkers for depression by multi-omics analysis of the human biological hippocampus and blood samples

    Grant-in-Aid for Early-Career Scientists  2025

  • investigation of novel biomarkers for depression by multi-omics analysis of the human biological hippocampus and blood samples

    Grant-in-Aid for Early-Career Scientists  2024

Incentive donations / subsidies

  • リキッドバイオプシーとミトコンドリア機能障害に基づく気分障害のバイオマーカー探索 双極性障害バイオマーカー探索

    先進医薬研究振興財団   精神薬療分野 一般研究助成金  2022

  • 層別化とマルチオミクスデータ統合解析による気分障害のバイオマーカー探索

    住友ファーマ   SMP研究サポート  2022